<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182413</url>
  </required_header>
  <id_info>
    <org_study_id>THN102-102</org_study_id>
    <nct_id>NCT03182413</nct_id>
  </id_info>
  <brief_title>Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation</brief_title>
  <official_title>Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de recherche biomédicale des armées (IRBA), Bretigny sur Orge, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a
      documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to
      placebo on parameters impaired by total sleep deprivation (SD, lasting 40h).

      Methods: 20 healthy male subjects participated in a double-blind, randomised,
      incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo
      (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg
      flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained attention (PVT)</measure>
    <time_frame>5 hours post treatment</time_frame>
    <description>Mean speed at the 10 min Psychomotor vigilance test (PVT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained attention (PVT) AUC</measure>
    <time_frame>AUC of PVT speed during TSD</time_frame>
    <description>AUC of speed values at the 10 min Psychomotor vigilance test (PVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental flexibility</measure>
    <time_frame>16,5 hours post treatment</time_frame>
    <description>Wisconsin card sorting test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental inhibition</measure>
    <time_frame>16,5 hours post treatment</time_frame>
    <description>GO-noGO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory</measure>
    <time_frame>16,5 hours post treatment</time_frame>
    <description>2-Back</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sleep Deprivation</condition>
  <arm_group>
    <arm_group_label>PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Modafinil 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 100/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 100 mg + 1 mg flecainide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 100/3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 100 mg + 3 mg flecainide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 100/9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 100 mg + 9 mg flecainide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <arm_group_label>MOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102</intervention_name>
    <arm_group_label>THN102 100/1</arm_group_label>
    <arm_group_label>THN102 100/3</arm_group_label>
    <arm_group_label>THN102 100/9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          1. Male subjects considered healthy and aged between 18 and 40 years

          2. Subject with a body mass index (BMI) between 18 and 30 kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Sauvet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche Biomedicale des Armees</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Françoise Brunner-Ferber, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Brunner Naga</affiliation>
  </overall_official>
  <link>
    <url>http://www.theranexus.com</url>
  </link>
  <reference>
    <citation>Duchêne A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, Piérard C, Lagarde D, Picoli C, Jeanson T, Mouthon F, Dauvilliers Y, Giaume C, Lin JS, Charvériat M. Impact of Astroglial Connexins on Modafinil Pharmacological Properties. Sleep. 2016 Jun 1;39(6):1283-92. doi: 10.5665/sleep.5854.</citation>
    <PMID>27091533</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>modafinil</keyword>
  <keyword>connexin</keyword>
  <keyword>sleep deprivation</keyword>
  <keyword>cognitive performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

